Pleckstrin 2 (PLEK2) is a critical intracellular adapter protein containing dual pleckstrin homology (PH) domains. Emerging as a pivotal driver in epithelial-mesenchymal transition (EMT), cancer metastasis, and JAK2-mediated erythropoiesis, PLEK2 represents a high-value oncology and myeloproliferative neoplasm (MPN) target. TarMart provides sequence-verified, high-purity recombinant proteins, lentivirus reagents, and validation tools to accelerate your PLEK2 drug discovery pipeline.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLEK2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLEK2 Recombinant Protein (Full-Length / PH Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. Available in E. coli and Insect cell expression systems. |
View PLEK2 Products |
| Gene Delivery | PLEK2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View PLEK2 Products |
| Benchmark Ab | Anti-PLEK2 Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View PLEK2 Products |
| Validator | PLEK2 siRNA Set For target knockdown verification in functional assays. |
View PLEK2 Products |
| Related Target A | JAK2 Upstream driver of PLEK2 expression in myeloproliferative neoplasms; crucial for synergy studies. |
View JAK2 Products |
| Related Target B | AKT1 Downstream effector of PLEK2-mediated PI3K signaling pathway activation. |
View AKT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Accessibility | Highly stable full-length and PH-domain truncated proteins optimized for SPR/MST binding assays. |
| Subfamily Off-Target Screening | High-purity PLEK1 recombinant protein panel available for counter-screening to ensure specificity. |
| Lack of Controls | Sequence-verified benchmark antibodies and validated siRNA sets included for phenotypic controls. |
| Conformational Cell-Based Assays | High-titer Lentivirus Premade Particles optimized for stable cell line generation (F-actin and migration assays). |
Live PLEK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PLEK2 therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapy to targeted small-molecule inhibitors and RNA interference (RNAi) therapeutics. As first-generation PI3K/AKT and JAK2 inhibitors face resistance challenges in the clinic, the next wave of R&D is targeting PLEK2 to disrupt the scaffold interaction that bypasses upstream pathway inhibition. Targeting the PH domain of PLEK2 offers a highly selective approach to block cell migration and survival in solid tumors and polycythemia vera.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PH Domain Inhibitor) | Academic Consortia, Biotech Startups | Myeloproliferative Neoplasms (MPN), Solid Tumors | Protein-Lipid Binding Assay (Need high-purity PH-domain recombinant proteins) |
| siRNA / RNAi | RNAi Therapeutics Developers | Colorectal Cancer, Glioma, NSCLC | Target Knockdown Validation (Need validated siRNA and Lentivirus controls) |
| Combination Therapies (with EGFR/JAK2i) | Oncology-focused Biopharma | Drug-Resistant EGFR-Mutant NSCLC | Synergy Screening (Need JAK2, AKT1, and EGFR target panels) |